MDA-7/IL-24 is the active component of INGN 241, an investigational cancer therapy currently in a Phase 2 trial in patients with malignant melanoma. A growing body of preclinical and clinical data indicates that INGN 241 stimulates the immune system to attack cancer cells through IL-24-dependent mechanisms.
"INGN 241 has been shown to exhibit a variety of anti-cancer activities, including inhibition of cancer cell growth and metastasis, reduction in the formation of new blood vessels necessary to support tumor growth and stimulation of the immune system to attack cancer," said Sunil Chada, Ph.D., Introgen's associate vice president, Clinical Research. "These new data detail the role that IL-24 plays in the normal immune response. We believe that further elucidation of the immune-enhancing activities of IL-24 further supports the development of INGN 241 as a novel cancer therapy that attacks tumors through several molecular pathways."
The paper describes the expression pattern of IL-24 in a variety of cell types following immune stimulation. Expression of IL-24 is increased by greater than 10,000-fold in specific cells that regulate the immune response. The data support an important role for IL-24 in regulating immune responses that occur as a result of viral or bacterial infection or tumor cell growth.
The studies were conducted in the laboratory of Elizabeth Grimm, Ph.D., Frances King Black Memorial Professor of Cancer Research in the Department of Experimental Therapeutics at M. D. Anderson Cancer Center. "Our data shows that activation of normal blood cells strongly induces IL-24 expression in key cellular regulators of the immune system. IL-24 induction is found as early as 1 hour after treatment, indicating that IL-24 may respond to "danger signals" from infections or cancer and amplify the immune response," said Dr. Grimm.
The mda-7 gene was discovered by the laboratory of Dr. Paul B. Fisher, professor of clinical pathology and the Michael and Stella Chernow Urological Cancer Research Scientist in the Departments of Neurological Surgery, Pathology and Urology at Columbia University. Introgen holds an exclusive worldwide license for all gene therapy applications from the Corixa Corporation.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using non-integrating tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Introgen holds a licensing agreement with M. D. Anderson to commercialize products based on licensed technologies, and has the option to license future technologies under sponsored research agreements. Dr. Grimm is a paid consultant to Introgen, and is a member of Introgen's Scientific Advisory Board. The University of Texas System Board of Regents own stock in Introgen. These arrangements are managed in accordance with M. D. Anderson's conflict of interest policies.